Shift from levothyroxine tablets to liquid formulation at breakfast improves quality of life of hypothyroid patients
Open accessAbstract
BACKGROUND: Until recently, treatment of hypothyroidism has been accomplished using monotherapy of synthetic L-thyroxine (L-T4) sodium tablets that should be taken 30-60 minutes before breakfast. Nowadays, a liquid preparation of levothyroxine is available and can effectively replace tablets without the need of waiting before having breakfast. Evidence of Quality of life (QoL) improvement when shifting from the former to the latter preparation, however, is still lacking. OBJECTIVE: The study aimed to assess changes in QoL of hypothyroid patients dissatisfied with their therapy with L-T4 sodium tablets who were switched from tablets taken 30-60 minutes before breakfast to liquid L-T4 at breakfast. METHODS: A total of 418 consecutive hypothyroid subjects treated by means of L-T4 tablets were asked about their satisfaction/dissatisfaction in order to take the medication 30-60 minutes before having breakfast. Overall, 110 patients (26.3%) complained of the timing of their L-T4 therapy (30-60 minutes before breakfast). A dedicated QoL questionnaire (ThyTSQ), taking just a few minutes to be filled in was then administered to these dissatisfied patients. They were therefore switched to L-T4 to be taken at breakfast. Aiming to avoid TSH elevation due to L-T4 tablets malabsorption caused by meal interference and gastric pH changes, patients were invited to take L-T4 liquid form, as this is claimed to be scarcely affected by the non-fasting state. The questionnaire (ThyTSQ) was administered again at the control visit 3 months later. TSH, FT4, FT3 serum concentrations and metabolic parameters were also recorded. RESULTS: An improved QoL, mainly due to an easier adherence to treatment, was reported by 66.6% of 102 patients who completed the study after shifting from taking medication 30-60 minutes before breakfast to at breakfast ingestion (P<0.01). An overall 10.7% of patients found the liquid formulation distasteful. Mean values of TSH, FT4, FT3, and of metabolic parameters did not significantly change but in eight patients (7.7%) who showed a TSH increase > 2mIU/L. CONCLUSION: In hypothyroid subjects dissatisfied with L-T4 tablets ingested 30-60 minutes before breakfast, the shift to the same dose of L-T4 in liquid form taken at breakfast improved QoL in the majority of patients, without affecting thyroid function.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Taken together, the convenience of the liquid preparation improves patient compliance.
“Taken together, these data show that the convenience of the liquid preparation improves patient compliance.”
From Levothyroxine: conventional and novel drug delivery formulations. (2023) · cites this paper as [212]
Approximately 10% of patients declared that the solution was distasteful and then returned to the solid LT4 formulation.
“Approximately 10% of patients declared that the solution was distasteful and then returned to the solid LT4 formulation (212).”
From Levothyroxine: conventional and novel drug delivery formulations. (2023) · cites this paper as [212]
A switch from 30 to 60 minutes before breakfast to the same dose of LT4 in the liquid form taken at breakfast could improve the quality of life in the majority of patients.
“In addition, a switch from 30 to 60 minutes before breakfast to the same dose of LT4 in the liquid form taken at breakfast could improve the quality of life in the majority of patients (212).”
From Levothyroxine: conventional and novel drug delivery formulations. (2023) · cites this paper as [212]
Taking a liquid LT4 formulation with breakfast, rather than LT4 tablets on an empty stomach before breakfast, was associated with greater patient satisfaction, as judged by significant improvements in three of seven subscores in the Underactive Thyroid Treatment Satisfaction Questionnaire.
“Guglielmi et al. open-label longitudinal study found that taking a liquid LT4 formulation with breakfast (rather than taking LT4 tablets on an empty stomach before breakfast) was associated with greater patient satisfaction, as judged by significant ( p < 0.01) improvements in three of the seven subscores in the Underactive Thyroid Treatment Satisfaction Questionnaire [ 26 ].”
From Factors influencing the levothyroxine dose in the hormone replacement therapy of primary hypothyroidism in adults (2022) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 37 · Cited by 57
Research works printed but not linked: 2
- [23]Ladenson P.W. Psychological well-being in patients. Clin. Endocrinol. (Oxf.) 2002 57 575 576 12390329
- [32]Cappelli C. Pirola I. Gandossi E. Formenti A. Castellano M. Oralliquidlevothyroxine treatment at breakfast: a mistake? Eur. J. Endocrinol. 2013 170 95 99 24123095
- Authors
- Guglielmi, R., Grimaldi, F., Negro, R., Frasoldati, A., Misischi, I., Graziano, F., Cipri, C., Guastamacchia, E., Triggiani, V., & Papini, E.
- Affiliations
- Ospedale Regina Apostolorum (IT)
- Endocrinology and Metabolic Disease Unit, Azienda Ospedaliero-Universitaria "S. Maria della Misericordia", Udine, Italy
- Ospedale Vito Fazzi (IT)
- Santa Maria Nuova Hospital (IT)
- University of Bari Aldo Moro (IT)
- Corresponding author
- Triggiani, Vincenzo
- ORCID
- Venue
- Endocrine, Metabolic & Immune Disorders - Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2018-04-02
- Volume
- 18
- Issue
- 3
- Pages
- 235-240
- ISSN
- 1871-5303 (ISSN-L)
- PMC
- PMC5997842
- OpenAlex
- W2785256773
- Cited by
- 57
- References
- 37
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 12 · 2023: 8 · 2022: 10 · 2021: 9 · 2020: 6 · 2019: 3 · 2018: 1
- FWCI
- 3.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc
- Locations
- Endocrine Metabolic & Immune Disorders - Drug Targets (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- hypothyroidism, levothyroxine, liquid formulation, tablet formulation, timing of drug administration, quality of life, medication adherence, thyroid-stimulating hormone, free thyroxine, free triiodothyronine, patient satisfaction, malabsorption, gastric pH, metabolic parameters, dose adjustment
- MeSH terms
- Adult, Drug Compounding, Female, Humans, Hypothyroidism, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Tablets, Thyroxine, Hormone Replacement Therapy, Drug Substitution, Breakfast
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review